Drug Delivery

Sep 16, 2015
Under terms of the agreement, Amgen will license Xencor’s XmAb technology platform for five Amgen programs and one Xencor program.
Sep 14, 2015
By BioPharm International Editors
Abenza acquired biopharmaceutical CDMO PacificGMP and expanded the company’s San Diego facility.
Sep 02, 2015
By BioPharm International Editors
The collaborative effort will be focused on fully humanized antibodies.
Aug 28, 2015
By BioPharm International Editors
The Pre-Connect Congress will explore pharma industry trends, such as mergers and acquisitions, the biologics market outlook, and innovation in drug delivery among others.
Aug 26, 2015
By BioPharm International Editors
Merus announced new investors and the sale of $80.5 million in shares to advance its immuno-oncology programs.
Aug 26, 2015
The company announced plans to begin PIONEER, a Phase IIIa program comprising seven trials of approximately 8000 people with type 2 diabetes.
Aug 03, 2015
By BioPharm International Editors
FDA issues draft guidance on dissolution testing for immediate-release solid oral dosage forms.
Aug 01, 2015
BioPharm International
Gene and cell therapies represent the next-generation treatments for a wide range of diseases, but one challenge in the development of these therapeutics is the controlled delivery to the targeted site to maximize expression or engraftment while limiting systemic exposure.
Aug 01, 2015
BioPharm International
The authors explore the use of statistical experimental design and multivariate analysis to develop a drug substance formulation matrix.
Aug 01, 2015
BioPharm International
Industry experts spoke to BioPharm International about the key considerations in the development of a drug-delivery device for a biologic drug, the importance of human factors engineering, the advantages of prefilled syringes, and the challenges in the manufacture of these devices.
native1_300x100
lorem ipsum